Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 2/20 | 0.63 |
| ▸ | PYGL | P06737 | 1/20 | 0.44 |
| ▸ | CXCR5 | P32302 | 11/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18614234 | 1.00 | GHSR (0.63) | GHSRPYGLCXCR5BACE1EPHX2 | |
| SCHEMBL29715495 | 1.00 | GHSR (0.63) | GHSRPYGLCXCR5BACE1EPHX2 | |
| SCHEMBL1425219 | 0.92 | GHSR (0.53) | GHSRCXCR5EPHX2 | |
| SCHEMBL29707280 | 0.92 | GHSR (0.53) | GHSRCXCR5EPHX2 | |
| SCHEMBL5196233 | 0.90 | GHSR (0.61) | GHSRPYGLBACE1EPHX2DRD2 | |
| SCHEMBL5404964 | 0.85 | GHSR (0.47) | GHSRCXCR5EPHX2CA12CA1 | |
| SCHEMBL8212655 | 0.84 | GHSR (0.48) | GHSRPYGL | |
| SCHEMBL1162409 | 0.84 | GHSR (0.48) | GHSRPYGLCXCR5BACE1EPHX2 | |
| SCHEMBL8581652 | 0.84 | GHSR (0.48) | GHSRPYGLCXCR5BACE1EPHX2 | |
| SCHEMBL1162415 | 0.84 | GHSR (0.48) | GHSRPYGLCXCR5BACE1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11845724-B2 | USP30 inhibitors and uses thereof | VINCERE BIOSCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2022-10-06 | — | — | US | disclosed |
| CN-115038688-A | USP30 inhibitors and uses thereof | 文森雷生物科学股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| EP-4028385-A1 | USP30 INHIBITORS AND USES THEREOF | Vincere Biosciences, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| US-11168321-B2 | Methods of creating and screening DNA-encoded libraries | X-CHEM, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| WO-2021050992-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021050992-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| US-20200385709-A1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | X-CHEM, INC. | 2020-12-10 | — | — | US | disclosed |
| EP-3211126-B1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | X CHEM INC (US) | 2020-10-21 | — | — | EP | disclosed |
| US-20120053091-A1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC | 2012-03-01 | — | — | US | disclosed |
| US-20120053091-A1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC | 2012-03-01 | — | — | US | disclosed |
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-2125757-A1 | MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008101665-A1 | MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1812383-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Smithkline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| US-7115767-B2 | Tetraline derivatives as ghrelin receptor modulators | ABBOTT LABORATORIES (US) | 2006-10-03 | — | — | US | disclosed |
| WO-2006052722-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20050014794-A1 | Tetraline derivatives as ghrelin receptor modulators | ABBVIE INC. | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168321-B2 | Methods of creating and screening DNA-encoded libraries | PCNA, DNA2, POLM | GHSR 4684/4885PYGL 3065/4885CXCR5 3036/4885 |
| US-20050014794-A1 | Tetraline derivatives as ghrelin receptor modulators | GPR119, GHSR, GIPR | GHSR 2/4885PYGL 1129/4885CXCR5 1553/4885 |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | PYGM, PYGL, GYS1 | GHSR 2194/4885PYGL 2/4885CXCR5 3905/4885 |
| US-20100240638-A1 | Organic Compounds and their uses | OAT, HAVCR2, CYP3A43 | GHSR 4593/4885PYGL 25/4885CXCR5 2929/4885 |
| US-20200385709-A1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | PCNA, DNA2, POLM | GHSR 4684/4885PYGL 3065/4885CXCR5 3036/4885 |
| US-11845724-B2 | USP30 inhibitors and uses thereof | USP30, USP28, USP1 | GHSR 3300/4885PYGL 2984/4885CXCR5 4588/4885 |
| US-20220315531-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | GHSR 3300/4885PYGL 2984/4885CXCR5 4588/4885 |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | GHSR 3300/4885PYGL 2984/4885CXCR5 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.